Association of Genetic Polymorphisms in the VKORC1 and CYP2C9 Genes with Warfarin Dosage in a Group of Kuwaiti Individuals

[1] Jin B(2014)The impact of VKORC1-1639G>A genetic polymorphism upon warfarin dose requirement in different ethnic populations Curr Med Res Opin. 8 1505-1511

[2] Hong Y(2014)Pharmacogenomics, ancestry and clinical decision making for global populations Pharmacogenomics J. 3 217-222

[3] Zhu J(2011)Population diversity and the performance of warfarin dosing algorithms Br J Clin Pharmacol 72 451-453

[4] Li Y(2004)Identification of the gene for vitamin K epoxide reductase Nature. 427 541-544

[5] Shi H-M(2010)Cytochrome P450 2C9-CYP2C9 Pharmacogenet Genomics. 20 277-281

[6] Ramos E(2004)Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2 Nature. 427 537-541

[7] Doumatey A(2005)The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen Blood. 106 2329-2333

[8] Elkahloun AG(2005)Common VKORC1 and GGCX polymorphisms associated with warfarin dose Pharmacogenomics J. 5 262-270

[9] Shriner D(2011)Pharmacogenetics, pharmacogenomics, and individualized medicine Pharmacol Rev. 63 437-459

[10] Huang H(2012)Effect of genetic variants, especially CYP2C9 and VKORC1, on the pharmacology of warfarin Semin Thromb Hemost 8 893-904

[1] Jin B(2014)The impact of VKORC1-1639G>A genetic polymorphism upon warfarin dose requirement in different ethnic populations Curr Med Res Opin. 8 1505-1511

[2] Hong Y(2014)Pharmacogenomics, ancestry and clinical decision making for global populations Pharmacogenomics J. 3 217-222

[3] Zhu J(2011)Population diversity and the performance of warfarin dosing algorithms Br J Clin Pharmacol 72 451-453

[4] Li Y(2004)Identification of the gene for vitamin K epoxide reductase Nature. 427 541-544

[5] Shi H-M(2010)Cytochrome P450 2C9-CYP2C9 Pharmacogenet Genomics. 20 277-281

[6] Ramos E(2004)Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2 Nature. 427 537-541

[7] Doumatey A(2005)The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen Blood. 106 2329-2333

[8] Elkahloun AG(2005)Common VKORC1 and GGCX polymorphisms associated with warfarin dose Pharmacogenomics J. 5 262-270

[9] Shriner D(2011)Pharmacogenetics, pharmacogenomics, and individualized medicine Pharmacol Rev. 63 437-459

[10] Huang H(2012)Effect of genetic variants, especially CYP2C9 and VKORC1, on the pharmacology of warfarin Semin Thromb Hemost 8 893-904